Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$23.41 USD
+0.68 (2.99%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $23.47 +0.06 (0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Bicycle Therapeutics PLC Sponsored ADR [BCYC]
Reports for Purchase
Showing records 1 - 20 ( 100 total )
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Catalyst-Rich 2H24; New $55 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
RD Day Highlights BT8009s Competitive Difference and Pipeline Potentials Beyond Urothelial Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BCYC 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Expediting BT8009 Development in mUC; RD Day on December 14; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Developing a Novel Radio-Conjugate Platform; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Durable Efficacy and Favorable Safety Data Validate BT8009 Potential in UC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Nectin-4 Program Dose Escalation Begins. Additional RECIST Responses in Phase I
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
BT8009 Clinical Update Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
3Q22: Clinical Progress Continues In All Programs. Q3 Update
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Potential of BT5528 in Ovarian and Urothelial Cancers Validated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Update of a BICYCLE Against Eph-Expressing Cancers
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
BT5228 Expansion Study Initiated; Genentech Collaboration Broadened; Lower PT to $57; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Bicycle Therapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
2Q22: Clinical Programs Progress-Data from Two Programs Later in 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T